艾美赛珠单抗预防治疗血友病A伴或不伴FVIII抑制物的长期结局:HAVEN 1-4研究汇总分析
该汇总分析纳入HAVEN 1-4研究中401例伴或不伴FVIII抑制物的儿童和成人血友病A患者,中位疗效期120.4周,模型治疗年出血率(ABR)为1.4(95%CI 1.1-1.7),第121-144周平均治疗ABR为0.7(95%CI 0-5.0),82.4%无治疗性出血,艾美赛珠单抗耐受良好,未发现新安全性问题。
要点
- 艾美赛珠单抗预防治疗使模型治疗ABR维持在1.4,长期观察中ABR下降并稳定在<1。
- 第121-144周,82.4%患者无治疗性出血,97.6%治疗性出血≤3次,94.1%无目标关节出血。
- 安全性可控,未因不良事件停药,血栓性微血管病和血栓栓塞事件均与aPCC使用相关。
核心结论
- 艾美赛珠单抗预防治疗在伴或不伴FVIII抑制物的各年龄段血友病A患者中维持低出血率且耐受良好,未发现新安全性问题。
研究设计与样本
- 汇总HAVEN 1、2、3、4四项3期研究(NCT02622321、NCT02795767、NCT02847637、NCT03020160)中401例儿童和成人血友病A患者,伴或不伴FVIII抑制物。
主要发现
- 中位疗效期120.4周(四分位距89.0-164.4),模型治疗ABR为1.4(95%CI 1.1-1.7)。
- 按24周治疗间隔分析,ABR下降并稳定在<1;第121-144周(n=170)平均治疗ABR为0.7(95%CI 0-5.0)。
- 第121-144周,82.4%参与者无治疗性出血,97.6%治疗性出血≤3次,94.1%无治疗性目标关节出血。
- 目标关节出血大幅减少;艾美赛珠单抗耐受良好,除先前描述的5例不良事件外无参与者因不良事件停药。
- 数据截止时报告3例血栓性微血管病(其中1例伴致命性直肠出血)和2例血栓栓塞事件,均与活化凝血酶原复合物浓缩物使用相关,另有1例心肌梗死和1例静脉装置闭塞。
临床怎么用
- 艾美赛珠单抗预防治疗可考虑用于伴或不伴FVIII抑制物的儿童和成人血友病A患者,以维持低出血率。
- 使用艾美赛珠单抗时需警惕与活化凝血酶原复合物浓缩物相关的血栓性微血管病和血栓栓塞事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prophylaxis with emicizumab, a subcutaneously administered bispecific humanized monoclonal antibody, promotes effective hemostasis in persons with hemophilia A (PwHAs). The primary efficacy, safety, and pharmacokinetics of emicizumab were reported previously, but long-term data were limited. Here, data from 401 pediatric and adult PwHAs with/without factor VIII (FVIII) inhibitors who were enrolled in the phase 3 HAVEN 1, HAVEN 2, HAVEN 3, and HAVEN 4 studies (NCT02622321, NCT02795767, NCT02847637, NCT03020160) have been pooled to establish a long-term efficacy, safety, and pharmacokinetics profile. Across a median efficacy period of 120.4 weeks (interquartile range, 89.0-164.4) (data cutoff 15 May 2020), the model-based treated annualized bleed rate (ABR) was 1.4 (95% confidence interval [CI], 1.1-1.7). ABRs declined and then stabilized at <1 in an analysis of 24-week treatment intervals; at weeks 121 to 144 (n = 170), the mean treated ABR was 0.7 (95% CI, 0-5.0). During weeks 121 to 144, 82.4% of participants had 0 treated bleeds, 97.6% had ≤3 treated bleeds, and 94.1% reported no treated target joint bleeds. Bleeding into target joints decreased substantially. Emicizumab was well tolerated, and no participant discontinued because of adverse events beyond the 5 previously described. This data cutoff includes the previously reported 3 thrombotic microangiopathies (one in the PwHA with fatal rectal hemorrhage) and 2 thromboembolic events, all associated with activated prothrombin complex concentrate use, as well as a myocardial infarction and a venous device occlusion. With 970.3 patient-years of exposure, emicizumab prophylaxis maintained low bleed rates in PwHAs of all ages with/without FVIII inhibitors and remains well tolerated, with no new safety concerns identified.
引用
- Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021. PMID: 33512413. doi:10.1182/blood.2020009217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。